Still, multiple questions, including the capacity of Claramine to inhibit IL13Rα2 negative tumors or the potential synergy with chemotherapeutic drugs like temozolomide or to overcome temozolomide-resistant tumors in GBM remain unanswered and will require further experimentation. This evidence concerns the gene IL13RA2 and glioblastoma.